Loading...

Progenics Pharmaceuticals

DB:PGP
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PGP
DB
$413M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
PGP Share Price and Events
7 Day Returns
-4.7%
DB:PGP
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-25.9%
DB:PGP
-10.6%
DE Biotechs
-6.2%
DE Market
PGP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Progenics Pharmaceuticals (PGP) -4.7% 9.5% 5.2% -25.9% -11.7% 75.9%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • PGP underperformed the Biotechs industry which returned -10.6% over the past year.
  • PGP underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
PGP
Industry
5yr Volatility vs Market

PGP Value

 Is Progenics Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Progenics Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Progenics Pharmaceuticals.

DB:PGP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PGP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 21%) (10.81%))
1.384
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.38
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.384 * 5.96%)
8.48%

Discounted Cash Flow Calculation for DB:PGP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Progenics Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:PGP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.48%)
2019 -47.50 Analyst x1 -43.79
2020 -14.90 Analyst x2 -12.66
2021 64.60 Analyst x1 50.61
2022 82.90 Analyst x1 59.87
2023 101.20 Analyst x1 67.38
2024 115.36 Est @ 13.99% 70.81
2025 126.74 Est @ 9.86% 71.71
2026 135.58 Est @ 6.97% 70.72
2027 142.29 Est @ 4.95% 68.42
2028 147.32 Est @ 3.53% 65.31
Present value of next 10 years cash flows $468.39
DB:PGP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $147.32 × (1 + 0.23%) ÷ (8.48% – 0.23%)
$1,790.37
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,790.37 ÷ (1 + 8.48%)10
$793.67
DB:PGP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $468.39 + $793.67
$1,262.06
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,262.06 / 84.54
$14.93
DB:PGP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PGP represents 0.875x of NasdaqGS:PGNX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.875x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 14.93 x 0.875
€13.06
Value per share (EUR) From above. €13.06
Current discount Discount to share price of €4.27
= -1 x (€4.27 - €13.06) / €13.06
67.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Progenics Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €4.27 vs Future cash flow value of €13.06
Current Discount Checks
For Progenics Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Progenics Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Progenics Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Progenics Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Progenics Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PGP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.87
NasdaqGS:PGNX Share Price ** NasdaqGS (2019-04-23) in USD $4.88
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Progenics Pharmaceuticals.

DB:PGP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PGNX Share Price ÷ EPS (both in USD)

= 4.88 ÷ -0.87

-5.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Progenics Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Progenics Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Progenics Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:PGP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
62.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Progenics Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Progenics Pharmaceuticals's assets?
Raw Data
DB:PGP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.20
NasdaqGS:PGNX Share Price * NasdaqGS (2019-04-23) in USD $4.88
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:PGP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PGNX Share Price ÷ Book Value per Share (both in USD)

= 4.88 ÷ 1.20

4.08x

* Primary Listing of Progenics Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Progenics Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Progenics Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Progenics Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PGP Future Performance

 How is Progenics Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Progenics Pharmaceuticals expected to grow at an attractive rate?
  • Progenics Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Progenics Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Progenics Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PGP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PGP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 62.3%
DB:PGP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 38.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PGP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PGP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 232 97 3
2022-12-31 197 73 3
2021-12-31 143 49 5
2020-12-31 89 -49 -11 5
2019-12-31 38 -50 -50 6
DB:PGP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 16 -47 -68
2018-09-30 16 -50 -56
2018-06-30 14 -53 -47
2018-03-31 13 -55 -48
2017-12-31 12 -54 -51
2017-09-30 12 -49 -56
2017-06-30 64 5 -4
2017-03-31 69 14 7
2016-12-31 69 20 11
2016-09-30 70 17 11
2016-06-30 17 -32 -35
2016-03-31 11 -37 -42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Progenics Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Progenics Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PGP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Progenics Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PGP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.02 1.31 0.79 3.00
2022-12-31 0.79 0.98 0.62 3.00
2021-12-31 0.54 0.89 0.19 3.00
2020-12-31 -0.12 0.57 -0.59 5.00
2019-12-31 -0.59 -0.42 -0.68 5.00
DB:PGP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.87
2018-09-30 -0.75
2018-06-30 -0.65
2018-03-31 -0.68
2017-12-31 -0.73
2017-09-30 -0.79
2017-06-30 -0.06
2017-03-31 0.10
2016-12-31 0.15
2016-09-30 0.16
2016-06-30 -0.51
2016-03-31 -0.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Progenics Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Progenics Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Progenics Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PGP Past Performance

  How has Progenics Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Progenics Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Progenics Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Progenics Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Progenics Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Progenics Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Progenics Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PGP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 15.62 -67.66 31.43 33.15
2018-09-30 16.27 -55.62 28.26 36.50
2018-06-30 13.65 -46.61 27.15 38.75
2018-03-31 12.54 -48.08 25.91 40.69
2017-12-31 11.70 -51.01 26.91 40.59
2017-09-30 12.46 -55.55 22.71 42.25
2017-06-30 63.62 -3.90 23.97 41.73
2017-03-31 69.33 7.10 23.23 38.43
2016-12-31 69.43 10.81 25.66 35.27
2016-09-30 69.87 10.86 22.40 55.16
2016-06-30 17.42 -35.45 19.75 45.33
2016-03-31 10.88 -41.51 20.28 37.35
2015-12-31 8.68 -39.11 18.18 28.20
2015-09-30 3.01 -44.14 18.76
2015-06-30 43.27 2.85 18.08
2015-03-31 42.81 3.47 15.81
2014-12-31 44.38 4.41 15.49 28.59
2014-09-30 47.92 8.04 14.41
2014-06-30 7.13 -39.44 13.64
2014-03-31 7.45 -40.63 14.44
2013-12-31 7.86 -42.57 15.54
2013-09-30 13.78 -34.35 14.30
2013-06-30 14.03 -35.15 15.18
2013-03-31 14.05 -33.60 14.55
2012-12-31 14.05 -35.43 15.21
2012-09-30 7.36 -45.85 15.79
2012-06-30 12.05 -45.98 15.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Progenics Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Progenics Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Progenics Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Progenics Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Progenics Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PGP Health

 How is Progenics Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Progenics Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Progenics Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Progenics Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Progenics Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Progenics Pharmaceuticals Company Filings, last reported 3 months ago.

DB:PGP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 101.08 44.60 137.69
2018-09-30 114.88 46.55 148.85
2018-06-30 62.83 47.64 87.49
2018-03-31 60.62 49.75 83.43
2017-12-31 63.45 49.69 90.64
2017-09-30 60.08 49.63 98.28
2017-06-30 74.55 49.56 113.96
2017-03-31 89.26 48.85 126.31
2016-12-31 104.76 49.45 138.91
2016-09-30 111.03 0.00 98.89
2016-06-30 73.84 0.00 60.15
2016-03-31 78.50 0.00 65.68
2015-12-31 90.66 0.00 74.10
2015-09-30 96.66 0.00 90.44
2015-06-30 105.29 0.00 99.31
2015-03-31 115.47 0.00 108.43
2014-12-31 124.91 0.00 119.30
2014-09-30 135.82 0.00 87.44
2014-06-30 98.22 0.00 85.35
2014-03-31 107.89 0.00 94.04
2013-12-31 78.98 0.00 65.86
2013-09-30 86.89 0.00 75.60
2013-06-30 91.28 0.00 79.22
2013-03-31 67.29 0.00 55.28
2012-12-31 66.57 0.00 58.84
2012-09-30 42.65 0.00 41.10
2012-06-30 52.97 0.00 47.82
  • Progenics Pharmaceuticals's level of debt (44.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 44.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Progenics Pharmaceuticals has sufficient cash runway for 2.9 years based on current free cash flow.
  • Progenics Pharmaceuticals has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 36% each year.
X
Financial health checks
We assess Progenics Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Progenics Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PGP Dividends

 What is Progenics Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Progenics Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Progenics Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Progenics Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Progenics Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PGP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PGP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Progenics Pharmaceuticals has not reported any payouts.
  • Unable to verify if Progenics Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Progenics Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Progenics Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Progenics Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Progenics Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Progenics Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Progenics Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PGP Management

 What is the CEO of Progenics Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Baker
COMPENSATION $2,313,136
AGE 63
TENURE AS CEO 8.1 years
CEO Bio

Mr. Mark R. Baker, J.D. has been the Chief Executive Officer at Progenics Pharmaceuticals, Inc since March 2011 and served as its President from September 2009 to March 3, 2011. Mr. Baker served as a Secretary and General Counsel of Progenics Pharmaceuticals, Inc. since June 20, 2005 and also served as its Executive Vice President-Corporate from 2008 to 2009. He served as Senior Vice President of Progenics Pharmaceuticals Inc., since June 20, 2005. He served as Chief Legal Officer and Senior Vice President - ContiGroup of Contitrade Services Corp. from September 1997 to August 2001 and was responsible for legal affairs and corporate governance, business development & licensing and intellectual property. Mr. Baker has over 25 years of legal experience, including 21 years with Dewey Ballantine LLP where he represented Progenics in its 1997 initial public offering, along with many other clients in the biotechnology field, including biotech companies, investment banks, consultants and venture capital firms. His practice at Dewey Ballantine LLP included work in the fields of corporate structures, capital raising, mergers and acquisitions, joint ventures and technology and product licensing. During his tenure at Dewey Ballantine LLP, he served in the capacity of Partner and Chairman of the Capital Markets Group. Mr. Baker began his career in 1979 as a corporate lawyer with the law firm Dewey Ballantine in New York, where he was a Partner and Co-Chairman of the Capital Markets Group, among other positions, serving through August 1997. In 1997, he joined ContiGroup Companies, Inc. (formerly Continental Grain Company). He joined Progenics Pharmaceuticals, Inc. on June 20, 2005. He served as Executive Vice President and Secretary of ContiGroup Companies Inc. from September 1997 to August 2001. Mr. Baker served as Chief Business Officer, Treasurer and Secretary of New York Trans Harbor LLC, a privately-held ferry operation in New York City operating under the name New York Water Taxi from January 2003 to June 2005. He has been the Non-Executive Chairman and Director of Contitrade Services Corp. since July 1999. He serves as the Chairman of ContiFinancial Corporation and has been its Director since July 1999. He has been a Director of EXINI Diagnostics AB (publ) since November 25, 2015. He has been a Director of Progenics Pharmaceuticals Inc. since September 2009. He served as a Director of New York Water Taxi, PSF Group Holdings and Murphy-Brown of Missouri, LLC. He served as a Director of Trans Harbor LLC from January 2003 to June 2005. Mr. Baker earned his J.D. at Columbia University School of Law where he was a Stone Scholar and an A.B. degree in History and Biochemistry at Columbia College in New York.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Progenics Pharmaceuticals management team in years:

1
Average Tenure
57
Average Age
  • The average tenure for the Progenics Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Mark Baker

TITLE
CEO & Director
COMPENSATION
$2M
AGE
63
TENURE
8.1 yrs

Pat Fabbio

TITLE
Executive VP & CFO
COMPENSATION
$1M
AGE
50
TENURE
3.4 yrs

Vivien Wong

TITLE
Executive Vice President of Development
COMPENSATION
$1M
AGE
61

Bryce Tenbarge

TITLE
Senior Vice President of Commercial
COMPENSATION
$975K
AGE
45
TENURE
1 yrs

Ben Osorio

TITLE
Chief Operating Officer
COMPENSATION
$794K
AGE
61
TENURE
0.1 yrs

Melissa Downs

TITLE
Senior Manager of Investor Relations

Jessica Jensen

TITLE
Senior Vice President of Clinical Development
TENURE
1 yrs

Asha Das

TITLE
Chief Medical Officer
AGE
53
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Progenics Pharmaceuticals board of directors in years:

9.6
Average Tenure
66
Average Age
  • The tenure for the Progenics Pharmaceuticals board of directors is about average.
Board of Directors

Peter Crowley

TITLE
Chairman
COMPENSATION
$371K
AGE
59
TENURE
8.8 yrs

Mark Baker

TITLE
CEO & Director
COMPENSATION
$2M
AGE
63
TENURE
9.6 yrs

Steve Goff

TITLE
Chairman of The Virology Scientific Advisory Board
COMPENSATION
$120K
AGE
66
TENURE
28 yrs

David Scheinberg

TITLE
Director & Member of Cancer Scientific Advisory Board
COMPENSATION
$176K
AGE
62
TENURE
23.3 yrs

Mike Kishbauch

TITLE
Director
COMPENSATION
$171K
AGE
69
TENURE
5.6 yrs

Robin Weiss

TITLE
Member of Virology Scientific Advisory Board

Sherie Morrison

TITLE
Member of Virology Scientific Advisory Board

John Mendelsohn

TITLE
Member of Cancer Scientific Advisory Board
AGE
81

Warren Heston

TITLE
Member of Cancer Scientific Advisory Board

Phil Livingston

TITLE
Member of Cancer Scientific Advisory Board
AGE
75
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Progenics Pharmaceuticals insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Apr 19 Buy Lte Partners, Llc Company 11. Mar 19 04. Apr 19 1,023,796 €4.46 €4,224,049
05. Apr 19 Buy Velan Capital, L.P. Company 07. Feb 19 03. Apr 19 4,535,700 €4.48 €0
05. Apr 19 Buy Virinder Nohria Individual 20. Feb 19 20. Mar 19 110,000 €4.17 €450,811
X
Management checks
We assess Progenics Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Progenics Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PGP News

Simply Wall St News

PGP Company Info

Description

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company’s product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Details
Name: Progenics Pharmaceuticals, Inc.
PGP
Exchange: DB
Founded: 1986
$368,175,208
84,542,514
Website: http://www.progenics.com
Address: Progenics Pharmaceuticals, Inc.
One World Trade Center,
47th Floor,
New York City,
New York, 10007,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PGNX Common Stock Nasdaq Global Select US USD 19. Nov 1997
DB PGP Common Stock Deutsche Boerse AG DE EUR 19. Nov 1997
LSE 0KOA Common Stock London Stock Exchange GB USD 19. Nov 1997
Number of employees
Current staff
Staff numbers
79
Progenics Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:47
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.